๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Orthofix Medical Inc. (OFIX)
NASDAQ: OFIX ยท Real-Time Price ยท USD
6.07
-0.27 (-4.26%)
Nov 20, 2026, 4:00 PM EST - Market closed

Orthofix Medical Earnings Call Transcripts

Fiscal Year 2026

  • Q3 sales rose 2.3% YoY, but spine softness and supplier delays pressured results and lowered FY guidance. Limb Reconstruction and Therapeutic Solutions grew; recovery actions center on core distributors, supply availability, and the VIRATA launch.

  • EBITDA has more than doubled in two years, with updated guidance reflecting reimbursement restoration, European MDR inventory purchases, and segment strengths offset by U.S. spine distributor declines. Regulatory reversals and product innovation are driving optimism, with a focus on organic growth and strategic capital allocation.

  • Second quarter results showed 5% net sales growth year-over-year, with strong gains in limb reconstruction and spine fixation, and Medicare reimbursement restored for bone growth stimulators. Guidance was raised for both revenue and EBITDA, though softness among smaller U.S. spine distributors remains a headwind.

  • Leadership emphasized operational stabilization, innovation, and commercial optimization. Major launches like Virata and 7D are set to drive growth, while cost discipline and distribution consolidation support profitability. CMS reimbursement changes impact guidance, but long-term outlook remains positive.

  • Q1 2026 saw 3% net sales growth, margin expansion, and strong execution, with top distributor partners driving significant gains. Guidance for 2026 is reaffirmed, expecting accelerating growth and margin improvement, supported by innovation and operational discipline.

  • Leadership transformation and commercial realignment have driven margin expansion and set the stage for multi-year growth, with over a dozen product launches and a focus on high-value segments. Financial targets include 6.5%-7.5% sales CAGR and mid-teens EBITDA margin by 2028.

  • Strong operational progress and financial discipline led to growth across all segments, with channel optimization and innovation driving future momentum. U.S. limb reconstruction is a major growth focus, while 7D technology and biologics see renewed investment. Long-range goals were extended to 2028 to fully realize channel upgrades.

Fiscal Year 2025

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021